As the Stryker hip recall clearly shows, devices can be implanted in thousands of people before their safety issues are apparent. Registries can be an effective tool for tracking the performance of artificial hips and other high-risk medical devices.
New York, NY (PRWEB) September 08, 2014
As Stryker hip lawsuits (http://www.injurybeacon.com/hip-replacement/stryker/lawsuit/) filed in the wake of the 2012 recall of Rejuvenate and ABG II Modular-Neck Hip Stems continue to mount in U.S. courts, Bernstein Liebhard LLP notes that a coalition of public interest and healthcare organizations is urging the U.S. Food & Drug Administration (FDA) to take steps that would encourage the development of medical device registries in this country. Among other things, the Pew Charitable Trust, the Blue Cross and Blue Shield Association and the Science Infrastructure Center at Weill Cornell Medical College's Medical Device Epidemiology Network point out that overseas device registries were instrumental in identifying the safety issues associated with metal hip implants that have emerged in recent years. According to the coalition, this example illustrates how medical device registries can benefit public health and post-market surveillance activities in the U.S. and abroad.*
“As the Stryker hip recall clearly shows, devices can be implanted in thousands of people before their safety issues are apparent. Registries can be an effective tool for tracking the performance of artificial hips and other high-risk medical devices,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm continues to offer free legal evaluations to individuals who were allegedly harmed by Stryker’s Rejuvenate and ABG II Modular-Neck Hip Stems.
Stryker Hip Recall
The Stryker hip recall was announced by the U.S. Food & Drug Administration on July 6, 2012, after post-market data indicated the metal hip components were prone to fretting and corrosion at the modular-neck junction. Stryker has warned that patients fitted with these implants may be at risk for pain, swelling and adverse local tissue reactions. All Rejuvenate and ABG II recipients have been advised to undergo medical testing to ensure their device is working properly, even if they have not experienced any symptoms that would suggest a problem with their hip.**
Since the Rejuvenate and ABG II stems were pulled from the market, more than 3,700 Stryker hip lawsuits have been filed in the U.S. on behalf of individuals who were allegedly injured by the devices. Court records indicate that some 2,064 cases are now pending in a multicounty litigation underway in New Jersey’s Bergen County Superior Court, where Bernstein Liebhard LLP is actively filing claims. (In Re Stryker Rejuvenate Hip Stem and the ABG II Modular Hip Stem Litigation, No. 296) Just over 1,700 additional cases involving Rejuvenate and ABG II hip stems have been filed in a federal multidistrict litigation established in U.S. District Court, District of Minnesota. (In re: Stryker Rejuvenate and ABG II Hip Implant Products Liability Litigation, No. 244)
According to court documents, all of these Stryker hip lawsuits allege that the Rejuvenate and ABG II stems were defectively designed and inadequately tested before they were brought to market. The complaints further allege that metal debris generated by the devices can result in a range of serious complications, including metallosis, osteolysis, chronic pain, and failure of the hip, which may result in the need for surgery to remove and replace the implant.
Recipients of Rejuvenate and ABG II hip stem may be entitled to compensation if they experienced any complications allegedly related to fretting and corrosion of the components. To learn more about the Stryker hip recall, please visit Bernstein Liebhard LLP’s website, or call 800-511-5092 to arrange for a free, no-obligation case review.
*pewtrusts.org/~/media/Assets/2014/09/Device-Registry-Conference-Report.pdf, Pew Charitable Trust, et al. September 2014
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP